Literature DB >> 2371495

Immunohistochemical analysis of human adenocarcinomas of the lung using the monoclonal antibody 44-3A6.

J A Radosevich1, M Noguchi, S T Rosen, Y Shimosato.   

Abstract

In this study, 39 primary, surgically resected, pulmonary adenocarcinomas of the following cell types were investigated: 19 Clara cell, 4 bronchial-gland, 15 goblet cell, and 1 type II alveolar epithelial adenocarcinoma. They were analyzed for the expression of the glandular differentiation-associated antigen recognized by the monoclonal antibody 44-3A6. Formalin-fixed, paraffin-embedded tissue sections were immunostained using the avidinbiotin complex/peroxidase method. All of the Clara cell tumors (19/19) expressed this antigen as well as 3/4 bronchial-gland tumors, as compared to only 2/15 goblet cell tumors. The single type II pneumocyte neoplasm studied was found to express this antigen. These findings parallel our earlier observations based on cytological features, and provide supportive evidence that there may be biological differences between human pulmonary adenocarcinomas and bronchioloalveolar carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2371495     DOI: 10.1159/000217653

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

1.  Cell cycle and electron microscopic evaluation of the adenocarcinoma antigen recognised by the monoclonal antibody 44-3A6.

Authors:  J A Radosevich; F S Siddiqui; S T Rosen; W J Kabat
Journal:  Br J Cancer Suppl       Date:  1991-06

Review 2.  Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer.

Authors:  James A Radosevich; Michael Babich
Journal:  Onco Targets Ther       Date:  2019-11-06       Impact factor: 4.147

3.  Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen.

Authors:  Michael Babich; Ankit Sharma; Tianhong Li; James A Radosevich
Journal:  Heliyon       Date:  2022-02-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.